DNAJA1 and cancer: After chemogenomic screening the NIH Approved Oncology collection and testing DNAJA1 inhibitors in CRPR-related models, the researchers delineated DNAJA1 as a hub for anticancer drug resistance and suggested that DNAJA1 inhibition is a potent strategy to sensitize cancer cells to chemotherapy [191].